Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06792708 · ClinicalTrials.gov registry record

Observational Study of LUMRYZ in Narcolepsy

A clinical trial of Narcolepsy, sponsored by Avadel.

Completed
Registry status
71
Enrollment target
12
Study locations

NCT06792708 is a study of Narcolepsy that has completed, run by Avadel. The registered enrollment target is 71 participants, below the 375-participant average among 12 other Narcolepsy trials with a reported enrollment target (81% lower). The trial reports 12 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06792708, a study of Narcolepsy, has completed, sponsored by Avadel.

COMPLETED
Registry status
71 participants
Enrollment target
12
Study locations

Study Summary

This is an observational study of LUMRYZ prescribed in clinical practice. Patients are asked if they would be willing to complete questionnaires over a 4-month period after starting LUMRYZ. The questionnaires ask about narcolepsy symptoms, experience with LUMRYZ, and quality of life.

Conditions Studied

Interventions

  • DRUG LUMRYZ

Study Locations (12)

Pennsylvania

  • Abington Neurological Associates - Abington
  • Pulmonology Associates, Inc. - Wynnewood
  • Respiratory Specialists - Wyomissing

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland
  • Ohio Sleep Medicine Institute - Dublin

Texas

  • Tricoastal Narcolepsy and Sleep Disorder Center - Sugar Land
  • Northwest Houston Neurology - Tomball

Florida

  • Jeremy D McConnell, MD PA - Bradenton

Michigan

  • Comprehensive Sleep Center - East Lansing

New Jersey

  • Patient First MD - Middletown

New York

  • Ghaly Sleep Management Services - East Syracuse

South Carolina

  • Bogan Sleep Consultants - Columbia

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2024-07-18
Est. Completion 2025-10-28

Sponsor

Avadel

4 total trials

What the Registry Record Tells You About NCT06792708

The ClinicalTrials.gov registry entry for NCT06792708 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 375-participant average among 12 other Narcolepsy trials with a reported enrollment target (81% lower). The listed sponsor is Avadel, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Narcolepsy appearing as the primary indexed condition, and to 1 intervention - of which LUMRYZ is the first listed.

NCT06792708 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Pennsylvania, Ohio, Texas.

Frequently Asked Questions

What is clinical trial NCT06792708 about?

NCT06792708 is a clinical study titled "Observational Study of LUMRYZ in Narcolepsy". This is an observational study of LUMRYZ prescribed in clinical practice. Patients are asked if they would be willing to complete questionnaires over a 4-month period after starting LUMRYZ. The questionnaires ask about narcolepsy symptoms, experience with LUMRYZ, and quality of life.

What is the current status of trial NCT06792708?

This trial is currently completed. The enrollment target is 71 participants. The study started on 2024-07-18. Estimated completion is 2025-10-28.

What conditions does trial NCT06792708 study?

This clinical trial studies the following conditions: Narcolepsy.

What interventions are being tested in trial NCT06792708?

The interventions under investigation include: LUMRYZ (DRUG).

Who is sponsoring clinical trial NCT06792708?

This trial is sponsored by Avadel, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06792708 being conducted?

This trial has 12 study locations across Florida, Michigan, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Narcolepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.